Clinical Trials Logo

Clinical Trial Summary

The aim of this study was to evaluate the efficacy and safety of liposomal doxorubicin in the treatment of desmoid tumors. Unless the subject withdraws from the trial voluntarily, or the researcher considers that the subject is not suitable for further trial, each subject will be treated until the disease progresses or the toxic and side effects caused by the drug are intolerable, and then enter the survival follow-up period


Clinical Trial Description

A randomized, double-blind, placebo-controlled study designed to compare (PFS) differences in progression-free survival in patients treated with liposome doxorubicin or placebo. PFS is defined as the time from randomization to the first occurrence of disease progression or death caused by any cause. If the disease is stable, PFS will be calculated at the time of the last follow-up in the study. Patients who have reached the maximum follow-up period and have no progress will be reviewed on the date of the last disease assessment. The crossover data of the patients were analyzed and summarized separately from the data of the main treatment process.In this study, 72 patients were expected to be enrolled in the group for 12 months and followed up for 24 months.Patients will be randomized to receive liposome adriamycin (50mg/m2) or intravenous placebo for a treatment cycle of once every 28 days.Duration of medication: a total of 6 cycles, or to the progression of the disease, tolerable toxicity, whichever occurs first.As the disease progresses, patients treated with placebo will be allowed to enter the unblinded liposome adriamycin group. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05561036
Study type Interventional
Source Sun Yat-sen University
Contact Jin Wang, M.D.
Phone 020-87343910
Email wangjin@sysucc.org.cn
Status Recruiting
Phase Phase 3
Start date September 29, 2020
Completion date March 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT00287846 - Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis Phase 1/Phase 2
Recruiting NCT06258421 - Burden of Disease and Living Situation in Desmoid Patients
Completed NCT00030680 - Radiation Therapy in Treating Patients With Aggressive Fibromatoses Phase 2
Recruiting NCT06081400 - Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting N/A
Active, not recruiting NCT04871282 - A Study of AL102 in Patients With Progressing Desmoid Tumors Phase 2/Phase 3
Recruiting NCT01567046 - Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas N/A
Completed NCT01137916 - Study to Evaluate Imatinib in Desmoid Tumors Phase 2
Completed NCT00002595 - Toremifene in Treating Patients With Desmoid Tumors Phase 2
Completed NCT03459469 - Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059 Phase 1
Completed NCT06195085 - CT-guided Radioactive Iodine-125 Seed Implantation for Recurrent Desmoid Tumors
Completed NCT01286662 - A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome N/A
Completed NCT01265030 - A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis Phase 1/Phase 2
Completed NCT00068419 - Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor Phase 2
Completed NCT04289077 - Quality of Life of Patients With Desmoid-type Fibromatosis
Completed NCT03190174 - Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers Phase 1/Phase 2
Completed NCT00003019 - Vinblastine and Methotrexate in Treating Children With Desmoid Tumors Phase 2
Recruiting NCT05949099 - Study of Cryoablation and Nirogacestat for Desmoid Tumor Phase 2
Active, not recruiting NCT02076906 - MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors Phase 1
Completed NCT00474994 - Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Phase 2
Active, not recruiting NCT03785964 - Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) Phase 3